Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). Meeting Abstract

sustainable development goals

publication date

  • February 20, 2021

webpage

published in

volume

  • 39

issue

  • 6